Detalhe da pesquisa
1.
Challenges of Incorporating Life Cycle Drug Pricing in Cost-Effectiveness Models: A Review of Methods and Modeling Suggestions.
Value Health
; 2024 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38513883
2.
"Stick or Twist?" Negotiating Price and Data in an Era of Conditional Approval.
Value Health
; 23(2): 191-199, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32113624
3.
Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum.
Pharmacoeconomics
; 42(2): 137-144, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37991631
4.
R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study.
Pharmacoeconomics
; 38(7): 765-776, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32236891
5.
Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK.
Appl Health Econ Health Policy
; 12(6): 611-22, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25086585
6.
A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom.
J Med Econ
; 17(4): 233-47, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24568188
7.
A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe.
Health Econ Rev
; 4: 6, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24949280
8.
Estimating the critical and sensitive periods of investment in early childhood: a methodological note.
Soc Sci Med
; 97: 316-24, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23591330
9.
The cost effectiveness of licensed oromucosal midazolam (Buccolam(®)) for the treatment of children experiencing acute epileptic seizures: an approach when trial evidence is limited.
Paediatr Drugs
; 15(2): 151-62, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23512129